Phenomex stock.

CELL Stock 12 Months Forecast. Based on 5 Wall Street analysts offering 12 month price targets for PhenomeX in the last 3 months. The average price target is $1.00 with a high forecast of $1.00 and a low forecast of $1.00. The average price target represents a 0.19% change from the last price of $1.00.PhenomeX Inc (CELL) stock activity in ARK Funds, current price, key statistics, news and description.PhenomeX Inc. CELL stock has more than doubled on Thursday after Bruker Corp. BRKR, +1.49% said it would acquire the Emeryville, Calif.-based, cell biology company for $1 a share in a deal that...BILLERICA, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per share in an all-cash transaction.The proposed acquisition values PhenomeX at a total …

Operating expenses were $53.3 million, inclusive of $3.7 million of stock-based compensation, for the second quarter of 2023, compared to $38.5 million, inclusive of $6.6 million of stock-based ...

WHEREAS, on the terms and subject to the conditions set forth in this Agreement, Merger Sub has agreed to commence (within the meaning of Rule 14d-2 under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”)), a cash tender offer to acquire any and all of the outstanding …

Item 8.01. Other Events. In November 2022, Berkeley Lights, Inc. became aware that an unknown third-party , impersonating a Company employee over e-mail through domain spoofing, fraudulently... | March 25, 2023PhenomeX optofluidic and proteomic technology to be featured in several poster and podium presentations. EMERYVILLE, Calif., May 11, 2023 /PRNewswire/ -- PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that it will participate in the 19 th annual Protein Engineering & Cell Therapy Summit (PEGS) …Item 7.01. Regulation FD Disclosure. Berkeley Lights, Inc. is aware of certain well-publicized recent developments involving Silicon Valley Bank . The Company considers its own banking exposure to... | May 2, 2023As the completion of this deal is anticipated in early Q4 2023, an arbitrage window emerges, offering a potential return of around 8% with the current share price per PhenomeX stock of about $0.93.

During its Q3 2023 earnings release, Bruker will provide more details on the expected Q4 2023 effect from PhenomeX. Today, Bruker reconfirms its medium-term financial outlook as issued at its Investor Day in June 2023. As a result of the transaction closing, PhenomeX common stock will no longer be listed for trading on the Nasdaq Global Market.

PhenomeX reiterates full year 2023 revenue to be in the range of $75 to $85 million dollars and updates its GAAP gross margin target range to be 57% to 60%, as a result of purchase price ...

Under the terms of the merger agreement entered into on December 21, 2022, IsoPlexis shareholders received, for each share of IsoPlexis stock, 0.612 shares of Berkeley Lights common stock (which will be automatically converted into shares of PhenomeX common stock). With the transaction complete, former Berkeley Lights and IsoPlexis shareholders ...Under the Warrant Certificate, the outstanding warrant (the “ IsoPlexis Warrant ”) to purchase shares of common stock, par value $0.001, of IsoPlexis (“ IsoPlexis Common Stock ”), issued by IsoPlexis to Perceptive was assumed by PhenomeX and converted into a warrant (the “ PhenomeX Warrant ”) to purchase shares of common stock, par ... PhenomeX Inc. CELL stock has more than doubled on Thursday after Bruker Corp. BRKR, +1.49% said it would acquire the Emeryville, Calif.-based, cell biology company for $1 a share in a deal that...BILLERICA, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per share in an all-cash transaction.The proposed acquisition values PhenomeX at a total …PhenomeX Inc. (CELL) delivered earnings and revenue surprises of -11.11% and 3.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?Feb 23, 2023 · Recent Highlights. Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;; Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profitable, and sustainable ... Return on Assets (ROA) of PhenomeX 2023 is 0. In 2023, PhenomeX's return on assets (ROA) was 0, a 0% increase from the 0 ROA in the previous year..

PhenomeX Inc. (Name of Subject Company) PhenomeX Inc. (Name of Persons Filing Statement) Common Stock, $0.00005 par value per share (Title of Class of Securities) 084310101 (CUSIP Number of Class of Securities) Scott Chaplin Chief Legal Officer PhenomeX Inc. 5858 Horton Street, Suite 320 Emeryville, California, 94608 (510) 858-2855Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...This column has become a great way to highlight amazing work our team does that you might not have heard about. Pivoting to virtual and remote work has been the reality for many people over the... | March 27, 2023Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.PhenomeX Inc is expected to release next earnings on -, with an earnings per share (EPS) estimate of-$0.20. Buy PhenomeX Inc (CELL) Stock See CELL stock price and …WebComplete Grid Battery Metals Inc. stock information by Barron's. View real-time CELL stock price and news, along with industry-best analysis. The stock market is getting a jolt from the inflation report. All three major U.S. stock indexes jumped more than 1% Tuesday morning, with the coming close to a 2% gain.

WHEREAS, on the terms and subject to the conditions set forth in this Agreement, Merger Sub has agreed to commence (within the meaning of Rule 14d-2 under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”)), a cash tender offer to acquire any and all of the outstanding …PhenomeX reiterates full year 2023 revenue to be in the range of $75 to $85 million dollars and updates its GAAP gross margin target range to be 57% to 60%, as a result of purchase price ...

Acquisition initiates Bruker’s entry into functional single-cell biology research solutions. BILLERICA, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)--#BRKR--Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per …--PhenomeX, Inc., a life sciences tools company, today reported financial results for the second quarter ended June 30, 2023. Achieved total revenue of $14.1 million for the second quarter of 2023 ...At the Effective Time, each outstanding option to purchase common stock, par value $0.001, of IsoPlexis (“IsoPlexis Common Stock”) (whether vested or unvested) held by continuing IsoPlexis employees with a per share exercise price less than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one …66.06. +0.97. +1.49%. PhenomeX Inc. (Nasdaq: CELL) today announced that Bruker Corporation (Nasdaq: BRKR) has commenced, through its wholly owned …WebPhenomeX was formed earlier this year when cell analysis firm Berkeley Lights closed its acquisition of proteomics firm IsoPlexis for $57.8 million in stock. In Q1, the firm reported revenues of $18.5 million, down 8 percent year over year.The combined company, which will be named PhenomeX (Nasdaq: CELL), will be a premier functional cell biology company that provides live cell biology research tools which deliver deep insights into ...Phenomex Inc share price live 0.9981, this page displays NASDAQ CELL stock exchange data. View the CELL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within …Sep 29, 2023 · View %COMPANY_NAME% CELL investment & stock information. Get the latest %COMPANY_NAME% CELL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... PHENOMEX INC (CELL ... PhenomeX, Inc. is a biology company that engages in the study of cells. Its tools and services allow the prevention and treatment of disease. The company ...We would like to show you a description here but the site won’t allow us.

PhenomeX Inc. CELL stock has more than doubled on Thursday after Bruker Corp. BRKR, +1.49% said it would acquire the Emeryville, Calif.-based, cell biology company for $1 a share in a deal that ...

-- Berkeley Lights and biotech start-up Aanika Biosciences said Monday they are working together to improve food safety, enable faster identification of outbreak sources and minimize the impact of...

Complete Grid Battery Metals Inc. stock information by Barron's. View real-time CELL stock price and news, along with industry-best analysis.PR Newswire (US) EMERYVILLE, Calif., Sept. 5, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL) today announced that Bruker Corporation (Nasdaq: BRKR) has commenced, through its wholly owned ...Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.Stock PhenomeX Inc. - Nyse. PhenomeX Inc. (BLI.NYSE) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock PhenomeX Inc. | …WebPhenomeX Inc. (BLI.NYSE) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock PhenomeX Inc. | Nyse: BLI | NyseThe combined company, which will be named PhenomeX (Nasdaq: CELL), will be a premier functional cell biology company that provides live cell biology research tools which deliver deep insights into ...Berkeley Lights (Nasdaq: BLI) and IsoPlexis (Nasdaq: ISO) today announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.PhenomeX. 05 Jun, 2023, 08:46 ET. Beacon Quest designed with affordable two-chip optofluidic system to accelerate the pace of scientific discovery across academic, non-profit, and government ...Financing. Details. PhenomeX Inc is a functional cell biology company that provides live cell biology research tools which deliver deep insi. Drug Discovery. Emeryville, CA. 285 As of 2022. 00000. 0000 0000-00-00.Berkeley Lights, Inc. entered into a collaboration with ChemPartner Co., Ltd. focused on accelerating ChemPartner's monoclonal antibody discovery workflow utilizing the Beacon® Optofluidic platform....Funding, Valuation & Revenue. 1 Fundings. Phenomenex's latest funding round was a Acquired for on October 12, 2016. Date. Round. Amount. Investors. Valuation. Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.These 20 growth stocks are worth considering on a pullback, says Citi MarketWatch. Thursday, August 17, 2023. 11:27 AM ET. PhenomeX stock rallies by 137% after buyout offer from Bruker MarketWatch. Friday, October 21, 2022. 09:19 AM ET. Bruker started at buy with $70 stock price target at UBS MarketWatch. Thursday, September …

43.0%. -36.3%. Market Cap. The market value of a company, in total dollars, also called "market capitalization." Market cap is calculated by taking a company's price per share and multiplying it ...PhenomeX, Inc. is a biology company that engages in the study of cells. Its tools and services allow the prevention and treatment of disease. The company was founded in 2011 and is headquartered ...PhenomeX Inc. (CELL) delivered earnings and revenue surprises of -11.11% and 3.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?Instagram:https://instagram. brokerage firms in indiamsft aiark innovation fundfreddie mac shares Berkeley Lights Inc (NASDAQ: BLI) has agreed to acquire IsoPlexis Corp (NASDAQ: ISO) in an all-stock transaction valued at $57.8 million. The combined company, which will be named PhenomeX, will ...During its Q3 2023 earnings release, Bruker will provide more details on the expected Q4 2023 effect from PhenomeX. Today, Bruker reconfirms its medium-term financial outlook as issued at its Investor Day in June 2023. As a result of the transaction closing, PhenomeX common stock will no longer be listed for trading on the Nasdaq Global Market. omnicarunder valued stocks Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that it will participate in the 19th annual Protein Engineering & Cell Therapy Summit (PEGS) Conference and Expo being ... best retirement plan providers Item 1.02 Termination of a Material Definitive Agreement. On June 30, 2023, PhenomeX Inc. (the "Company") repaid in full all outstanding indebtedness under the Second Amended and Restated Loan and Security Agreement (the "PhenomeX Credit Agreement "), dated as of March 21, 2023, among, inter alios, Company, IsoPlexis Corporation, a Delaware corporation and East West Bank, a California banking ...Sep 25, 2022 · Discover historical prices for CELL stock on Yahoo Finance. View daily, weekly or monthly format back to when PhenomeX Inc. stock was issued. PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced that the Company's technology was recently featured in a groundbreaking study published in Cell Reports titled ...